A Dab of MAB: Lecanemab, Aducanumab vs Standard of Care Treatment for Alzheimer Disease

Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.

Related Keywords

Texas ,United States ,American ,Mckenzie Erwin ,Duggan Evans ,Iwatsubot Lecanemab ,Lilly Donanemab ,Ashley Sturm ,S Budd Haeberlein ,Mayo Clinic Medical Center ,Alzheimer Association ,Guideline Development ,Drug Administration ,Clinical Dementia Rating Sum ,Primary Endpoints ,Austin College ,Clinical Pharmacist ,Mayo Clinic Medical ,Accessed July ,Implementation Subcommittee ,American Academy ,Budd Haeberlein ,Randomized Phase ,Early Alzheimer ,Summarized Data From ,Evaluate Safety ,Participants With Alzheimer ,Disease Who Had Previously Participated ,Aducanumab Studies ,Alzheimers Res ,Retrieved June ,New England ,